Stock Analysis

Despite Recent Gains, Aspira Women's Health Insiders Are Still Down US$43k

NasdaqCM:AWH
Source: Shutterstock

Insiders who bought US$100k worth of Aspira Women's Health Inc. (NASDAQ:AWH) stock in the last year recovered part of their losses as the stock rose by 20% last week. The purchase, however, has proven to be a pricey bet, with losses currently totalling US$43k.

While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we would consider it foolish to ignore insider transactions altogether.

See our latest analysis for Aspira Women's Health

Aspira Women's Health Insider Transactions Over The Last Year

The President Nicole Sandford made the biggest insider purchase in the last 12 months. That single transaction was for US$75k worth of shares at a price of US$0.76 each. That means that an insider was happy to buy shares at above the current price of US$0.40. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. In our view, the price an insider pays for shares is very important. As a general rule, we feel more positive about a stock if insiders have bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price.

Aspira Women's Health insiders may have bought shares in the last year, but they didn't sell any. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

insider-trading-volume
NasdaqCM:AWH Insider Trading Volume January 9th 2023

Aspira Women's Health is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Does Aspira Women's Health Boast High Insider Ownership?

For a common shareholder, it is worth checking how many shares are held by company insiders. We usually like to see fairly high levels of insider ownership. It appears that Aspira Women's Health insiders own 40% of the company, worth about US$20m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.

What Might The Insider Transactions At Aspira Women's Health Tell Us?

The fact that there have been no Aspira Women's Health insider transactions recently certainly doesn't bother us. But insiders have shown more of an appetite for the stock, over the last year. Insiders do have a stake in Aspira Women's Health and their transactions don't cause us concern. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Aspira Women's Health. You'd be interested to know, that we found 5 warning signs for Aspira Women's Health and we suggest you have a look.

But note: Aspira Women's Health may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.